6:09 PM
 | 
Sep 26, 2012
 |  BC Extra  |  Clinical News

UCB's anti-IL-6 mAb meets Phase IIb RA endpoint

UCB Group (Euronext:UCB) said subcutaneous olokizumab met the primary endpoint vs. placebo in a Phase IIb trial to treat moderate to severe active rheumatoid arthritis. The endpoint measured the reduction in Disease Activity Score...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >